Twelve patients, ten with common variable hypogammaglobulinaemia and two with hypogammaglobulinaemia secondary to chronic lymphocytic leukaemia (CLL), have been taught to self-infuse their intravenous immunoglobulin replacement therapy. Follow-up of these patients has shown that regular self-infusion at home is feasible and safe. There have been no anaphylactic or other serious reactions. Excellent patient compliance results from greater convenience and control over their own lives, in addition to time and money saved by the hospital.